[
    {
        "title": "Badve SV, Pascoe EM, Tiku A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. The New England journal of medicine 2020; 382: 2504-2513.",
        "paper_uid": "4b195d32",
        "pmid": "32579811",
        "reference": "Badve SV, Pascoe EM, Tiku A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. The New England journal of medicine 2020; 382: 2504-2513.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Doria A, Galecki A, Spino C, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England journal of medicine 2020; 382: 2493\u20102503.",
        "paper_uid": "92d86942",
        "pmid": "32579810",
        "reference": "Doria A, Galecki A, Spino C, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England journal of medicine 2020; 382: 2493\u20102503.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long - term follow - up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549.",
        "paper_uid": "d0103bae",
        "pmid": "25595565",
        "reference": "Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long - term follow - up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6 - Month, Double - Blind, Randomized, Placebo - Controlled Trial. Am J Kidney Dis 2015; 66: 945-950.",
        "paper_uid": "d14dd133",
        "pmid": "26233732",
        "reference": "Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6 - Month, Double - Blind, Randomized, Placebo - Controlled Trial. Am J Kidney Dis 2015; 66: 945-950.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.",
        "paper_uid": "767b33a2",
        "pmid": "16377385",
        "reference": "Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Yang H, Li R, Li Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China. International urology and nephrology 2023; 55: 1343-1352.",
        "paper_uid": "b4a1553e",
        "pmid": "36534221",
        "reference": "Yang H, Li R, Li Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China. International urology and nephrology 2023; 55: 1343-1352.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Jalal DI, Decker E, Perrenoud L, et al. Vascular function and uric acid - lowering in stage 3 CKD. Journal of the American Society of Nephrology 2017; 28: 943-952.",
        "paper_uid": "4409bf3a",
        "pmid": "27620990",
        "reference": "Jalal DI, Decker E, Perrenoud L, et al. Vascular function and uric acid - lowering in stage 3 CKD. Journal of the American Society of Nephrology 2017; 28: 943-952.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1382-1389.",
        "paper_uid": "9e5ec898",
        "pmid": "21719783",
        "reference": "Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1382-1389.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; 72: 798-810.",
        "paper_uid": "f4261f50",
        "pmid": "30177485",
        "reference": "Kimura K, Hosoya T, Uchida S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; 72: 798-810.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Wen H, Yongling Z, Shuying Z, et al. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy. Jornal Brasileiro de Nefrologia 2020; 42: 393 - 399.",
        "paper_uid": "5757e468",
        "pmid": "32701116",
        "reference": "Wen H, Yongling Z, Shuying Z, et al. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy. Jornal Brasileiro de Nefrologia 2020; 42: 393 - 399.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Beddhu S, Filipowicz R, Wang B, et al. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Canadian journal of kidney health and disease 2016; 3: 2054358116675343.",
        "paper_uid": "3f0f91a7",
        "pmid": "28270924",
        "reference": "Beddhu S, Filipowicz R, Wang B, et al. A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy. Canadian journal of kidney health and disease 2016; 3: 2054358116675343.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    }
]